Global Progress in the Fight Against Antimicrobial Resistance: A New Assessment
Antimicrobial resistance (AMR) remains a critical global public health challenge, but a recent comprehensive study offers a nuanced view of progress made in addressing it. Analyzing data from 193 countries between 2000 and 2021, researchers have evaluated national AMR governance and its impact on related outcomes, revealing both encouraging trends and areas needing urgent attention.
Strengthening Governance: A Five-Year Trend
The study, published in January 2026, indicates that governance of AMR surveillance in low- and middle-income countries (LMICs) generally strengthened over the five years to 2024, converging with that of high-income countries (HICs). This improvement is particularly notable in South-East Asia, which reported relatively strong gains – a striking exception to limited global progress in other regions. Specifically, progress was reported in strengthening underlying AMR surveillance systems in both human and animal health, as well as in regulatory frameworks for animal health.
Data Sources and Methodology
Researchers compiled a longitudinal dataset utilizing national AMR policy documents, the Tracking AMR Country Self-Assessment Survey (TrACSS), data from UNICEF, the Global AMR R&D Hub, and the GLASS database. The study period focused on 2017-2022, leveraging the availability of TrACSS data. A Delphi consultation involving 38 international experts helped refine a governance evaluation framework, ensuring a robust and internationally recognized standard for assessment.
The Role of the Fleming Fund
The effectiveness of major development aid interventions, such as the UK-funded Fleming Fund (FF), was also assessed. The research considered changes in responses to the TrACSS between 2019 and 2024, providing insights into how these programs are impacting national governance structures. The study highlights the importance of a ‘One Health’ approach, recognizing the interconnectedness of human, animal, and environmental health in addressing AMR.
Analyzing AMR-Related Outcomes
The study examined AMR prevalence, antimicrobial employ (AMU), and AMR-related mortality. Data on AMR prevalence was sourced from the Global Burden of Disease (GBD) study, supplemented by data from the Institute for Health Metrics and Evaluation and WHO Global TB Reports. AMU data included human, animal, and agricultural crop-production use, with complex imputation strategies employed to address missing data. Joinpoint regression analysis identified inflection points in AMR prevalence trends, revealing changes in the rate of resistance over time.
Addressing Data Gaps and Challenges
Researchers acknowledged the challenges of incomplete data, particularly regarding animal and agricultural AMU. Countries with structurally missing data were excluded from certain analyses to avoid bias. Sophisticated statistical methods, including ARIMA models and backcasting/forecasting techniques, were used to handle missing data and preserve temporal trends. The study also accounted for potential confounding factors, such as the COVID-19 pandemic.
A Focus on Policy and Implementation
The analysis of nearly 300 national policy documents revealed insights into policy design, and implementation. The study utilized a difference-in-differences methodology to estimate the association between National Action Plan (NAP) adoption and AMR-related outcomes, allowing for heterogeneous treatment effects. This approach helps determine whether NAPs are effectively translating into improved outcomes.
Latent Class Growth Modeling Reveals Trajectories
Latent class growth modeling identified distinct trajectories of AMR prevalence changes, allowing researchers to categorize countries based on their progress. This approach helps pinpoint which nations are demonstrating the most significant improvements and informs targeted interventions.
Future Trends and Implications
The study suggests a continued need for strengthening AMR governance, particularly in areas beyond surveillance systems and regulatory frameworks. A more holistic approach, integrating social and equity dimensions, is crucial. Further research is needed to understand the unintended consequences of AMR interventions and to develop more people-centered strategies. The convergence of LMIC and HIC governance suggests a potential for knowledge sharing and collaborative efforts to accelerate progress globally.
Frequently Asked Questions
What is AMR?
Antimicrobial resistance occurs when microorganisms like bacteria, viruses, fungi, and parasites change over time and no longer respond to medicines designed to kill them.
What is the TrACSS?
The Tracking AMR Country Self-Assessment Survey (TrACSS) is a tool used to assess a country’s capacity to address antimicrobial resistance.
What is the Fleming Fund?
The Fleming Fund is a UK-funded program aimed at combating antimicrobial resistance globally, primarily by strengthening surveillance systems in LMICs.
Explore further: Learn more about the Global Action Plan on Antimicrobial Resistance on the WHO website.
What are your thoughts on the progress being made in the fight against AMR? Share your comments below!
